You are here

  • Home
  • Archive
  • Volume 16, Issue Suppl 3
  • 0003: Gemcitabine-Paclitaxel-Carboplatin (TCG) VS. Paclitaxel-Carboplatin (TC) in Ovarian Cancer (OC): A Randomized Phase III Gcig Study (AGOOVAR-9, GINECO-TCG, NSGO-OC-0102)

Article info

Article menu
Download PDFPDF
ABSTRACT: Free Communications: Ovarian Cancer Saturday, October 14, 2006
0003: Gemcitabine-Paclitaxel-Carboplatin (TCG) VS. Paclitaxel-Carboplatin (TC) in Ovarian Cancer (OC): A Randomized Phase III Gcig Study (AGOOVAR-9, GINECO-TCG, NSGO-OC-0102)

Authors

Citation

Pujade-Lauraine E, Lueck HJ, Bertelsen K, et al
0003: Gemcitabine-Paclitaxel-Carboplatin (TCG) VS. Paclitaxel-Carboplatin (TC) in Ovarian Cancer (OC): A Randomized Phase III Gcig Study (AGOOVAR-9, GINECO-TCG, NSGO-OC-0102)
International Journal of Gynecologic Cancer 2006;16:599.
Online issue publication 
December 17, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2006 IGCS, International Journal of Gynecological Cancer